Table. 2.

Table. 2.

Demographic and clinical characteristics of patients with febrile neutropenic episodes in IVIG+ and IVIG− groups at the beginning of second-line treatment

IVIG+ (n=39) IVIG− (n=45) P-value
Sex (M/F) 24/15 19/26 0.086
Age (median, range) 11.5 (0.4-25.4) 11.8 (0.5-24.3) 0.796
Antibiotics 0.124
PIPC/TAZ (%) 26 (66.7) 22 (48.9)
MEPM (%) 13 (33.3) 23 (51.1)
Disease 0.078
ALL (%) 18 (46.2) 19 (42.2)
AML (%) 11 (28.2) 5 (11.1)
NHL (%) 6 (15.4) 9 (20.0)
Solid tumor (%) 3 (7.7) 3 (6.7)
AA (%) 1 (2.6) 3 (6.7)
Other (%) 0 (0) 6 (13.3)
Stem cell transplantation (yes) (%) 6 (15.4) 11 (24.4) 0.416
CV catheter (yes) (%) 38 (97.4) 44 (97.8) 1.000
WBC at the beginning of treatment (×109/L, median, range) 0.37 (0.01-14.00) 0.27 (0.01-4.92) 0.589
CRP at entry (mg/dL, median, range) 4.93 (0.05-29.96) 3.78 (0.05-28.49) 0.615
β-D glucan (pg/mL, range) 7.9 (1.6-53.2) 7.9 (1.6-20.9) 0.842
Procalcitonin (ng/mL, range) 0.24 (0.03-51.03) 0.22 (0.04-46.63) 0.935
IgG (mg/dL, range) 682 (59-1255) 664 (110-1502) 0.496

M, male; F, female; PIPC/TAZ, piperacillin tazobactam; MEPM, meropenem; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; AA, aplastic anemia; CV, central venous; WBC, white blood cell count; CRP, C-reactive protein; IgG, immunoglobulin G.

Clin Pediatr Hematol Oncol 2021;28:75-83
© 2021 Clin Pediatr Hematol Oncol